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KNOWLEDGE of the dose of X- or gamma rays sufficient to induce malignant
tumours in bones of humans and experimental animals is of practical and theo-
retical importance. Data on this subject are surprisingly limited and almnost all
of our information is based on not more than about 70 published cases of bone
tumours in man (Sabanas, Dahlin, Childs and Ivins, 1956) and on very scanty and
much less enlightening data from experimental animals. All of the bone tumours
known to have been produced by external irradiation in human beings have
occurred as a result of radiation therapy. The exact tissue dosages in most
instances are not known, but it is apparent that all cases occurred after relatively
large doses. The published figures range from 1400 to 10,000 roentgens (Cahan,
Woodard, Higinbotham, Stewart and Coley, 1948; Jones, 1953; Sabanas, et al.,
1956).
The data on bone tumours produced by external irradiation of experimental
animals are even more limited than the human data. Four malignant bone
tumours have been reported after local irradiation of rats and rabbits with X-
rays (Marie, Clunet and Roulot-LaPointe, 1910; Lacassagne and Vinzent, 1929;
Ludin, 1930; and Lacassagne, 1933). The dosages again were high, but it is not
possible to make reliable estimates of the tissue dosages in those experiments. In
addition, five osteogenic sarcomata have been observed byKoletsky and Gustafson
(1955) in a series of 123 Wistar rats exposed to 660 r of whole-body X-irradiation
(220 KVp.). No other data have been found in the literature with regard to the
production of bone tumours by either local or whole-body exposure to X- or
gamma rays.
An estimate of the true tissue dose in the bones of either animals or human
patients exposed to conventional X-rays (220 KVp.) is made difficult by the fact
that the energy absorbed in bone is about 2 to 3 times greater than that in the
soft tissues for the same dose of roentgens (Spiers, 1949). It is likely, therefore,
that the radiation doses received by the susceptible cells in the bones of many of
the cases under discussion were considerably greater, in general, than those cited
in the respective papers. The prevailing uncertainties regarding the dose required
to produce malignant bone tumours in experimental animals with external
irradiation and the absence of any morphological studies concerning the patho-
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genesis ofneoplasms under such conditions made it desirable to study this problem
in some detail.
Accordingly we endeavoured to produce bone tumours in rats by local irra-
diation with a relatively large single dose of gamma rays. Gamma rays were
chosen in order to avoid the aforementioned difficulties in dose estimation that
are encountered with conventional X-rays. A radio-iridium source was available
for the purpose. The absorption of gamma rays from iridium 192 is only about
10 per cent higher in bone than in soft tissue (as calculated from the data of
Spiers, 1949). A dose of 3000 roentgen was chosen because, on the basis of clinical
and experimental data (Woodard and Coley, 1947; Barr, Lingley and Gall,
1943; Sissons, 1956), it was thought that this dose would be large enough to
produce severe and permanent tissue damage without at the same time causing
excessive bone necrosis, fractures and other complications leading to premature
death of the animals. It also seemed desirable to use a dose level somewhat com-
parable to the human exposures and it can be seen that 3000 r is just about twice
as large as the lowest reported figure in the data on post-irradiation sarcoma in
man (Cahan et al., 1948). Although it would have been desirable to study the
effects of at least two different dose levels in sufficient numbers of animals, this
proved impractical. However, it was thought to be feasible to investigate simul-
taneously the subsidiary question whether hormone treatment of animals follow-
ing irradiation would have a measurable effect on the induction time and yield
of tumours. Bone growth and metabolism are known to be influenced by a number
of hormones and since abnormalities in hormonal balance are also known to be
important factors in the genesis of some tumours in other organ systems it was
decided to study the influence of two hormones on the induction of tumours.
The two hormones chosen for experimentation have a different and fairly specific
action on skeletal tissue: (1) growth hormone stimulates the growth of cartilage
(Evans, Becks, Asling, Simpson and Li, 1948) and periosteal osteogenesis (Becks,
Asling, Simpson, Li and Evans, 1949); (2) thyroxine acts on the turnover ofbone,
increasing the excretion of calcium and phosphorus, and producing morphological
evidence of excessive bone resorption (Follis, 1953).
METHODS
Female Wistar rats, 60 days old and weighing between 100-130 g. were irra-
diated with 3000 r to both knee joints from a Radio-Iridium teletherapy unit
(Freundlich and Haybittle, 1953) emitting primary gamma rays with a mean
energy of0.38 Mev. half-value layer 8.1 mm. Cu. (see Fig. 1). The dose rate varied
on different occasions from 35 to 42.5 r per minute, requiring an exposure of 70
to 85 minutes. A perspex frame was made on which the anaesthetized rats could
be fixed by bandage slings. Four rats were exposed simultaneously and a special
lead and perspex applicator was constructed so that the 4 pairs of knee joints
comprising the lower half of the femur and upper half of the tibia would be irra-
diated (Fig. 2). The animals were anaesthetized with either nembutal (0.1 ml./
100 g. I.P.), or with sodium amytal (7 mg./100 g. I.P.). The radiation was com-
pleted in 8 sessions all performed within a period of 15 days.
One hundred and thirty six (136) irradiated rats were divided into 4 groups,
A, B, C and D, and each group shared as evenly as possible the rats from the 8
radiation sessions. 34 rats from the same litters were allocated to the unirradiated
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control groups, E, F, G and H. Eighty days after irradiation, hormone injections
were begun.
Group A of 31 rats and control Group E of 5 rats were given daily injections
(except Sunday) of growth hormone subcutaneously in the flank in increasing
doses: 30 ,ug. per rat per day for the 1st week; 60 /tg. for the 2nd week; 120 ug.
for the 3rd and the 4th week; 240 ,/tg. for the 5th and 6th week; 360 /tg. for the
7th week; 480 ,tg. for the 8th week; 780/tg. for the 9th week and 1 mg. for the
10th week (a total of 20-58 mg. per rat in 10 weeks). The growth hormone used
was Somacton for 6 weeks, and for the last 4 weeks was a preparation made by the
Wilson Laboratories, Chicago, Illinois.
SPACE
PERSPEX-
TARGET
ZONE
FIG. 1.-Section of the radium-iridium teletherapy unit (Freundlich and Haybittle, 1953)
showing the gamma-ray source, the lead applicator, and the perspex frame to which the
rats were fastened.
Group B of 30 irradiated rats and Group F of 5 control animals were given
daily (except Sundays) subcutaneous injections into the flank of Na 1 Thyroxine
(Glaxo Laboratories Ltd.), dissolved in physiological saline containing 0.01 M
sodium carbonate, 20 ,tg. per rat per day for 3 weeks, 30 #g. for another 3 weeks,
and 45 /ug. for the last 4 weeks, making a total of 1.98 mg. per rat (10 mg./kg.),
over the 10 weeks.
Group C of 28 irradiated rats and Group G of 5 control rats were given a 10
weeks course of growth hormone injections identical with Groups A and E, and
followed by a 10 weeks course of thyroxine injections identical with Groups B
and F. Group D of 37 irradiated rats were injected daily with saline, half the
group were injected for 10 weeks and half for 20 weeks. A control group H of
19 unirradiated rats were injected with saline, halffor 10 weeks and the remainder
for 20 weeks.
216TUMOURS INDUCED BY GAMMA IRRADIATION OF BONES
All rats were weighed once a week and growth curves plotted for each cage
and each group.
Diagnostic X-rays were made of the legs and lower abdomen of each rat at
185, 280 and 386 days. The rats were anaesthetized with ether and rapidly posi-
tioned on the X-ray plate with cellotape. Both knees of each rat were palpated
at least once a week and the occurrence oftumours noted. As soonas itwas certain
FIG. 2.-Plan of the 4 rats fastened to the perspex frame by slings of bandage. The shaded
zones are the ports in the lead applicator. Both knee joints and 1 cm. of the adjacent
femoral and tibial shafts of each rat were irradiated.
that a tumour was rapidlygrowing the animal waskilled, aradiograph ofthe whole
animal was made, and autopsy performed. Both hind-legs of each rat were fixed
in formalin and after dissection they were decalcified with 3 per cent nitric acid,
embedded in celloidin, sectioned and stained with haematoxylin and eosin. Other
tissues, including the endocrine glands, were fixed in Suza solution and embedded
in paraffin. A few of the controls were killed from time to time to have animals
of comparable age to those ofthe irradiated groups, but most ofthe controls were
killed when all irradiated animals had died.
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RESULTS
1. Clinical observations on irradiated animals
All the irradiated rats showed complete depilation ofthe irradiated areas which
persisted for some weeks. In some cases, this went on to ulceration in the skin
creases. Discharging sinuses developed in a few rats which were later found to have
extensive destruction of the bones of the knees with loss of the femoral epiphysis
and a part of the femoral shaft. All these early lesions healed in time, but it was
obvious that the dose of radiation could have not been increased much above
3,000 r without the danger of localised destructive lesions in the majority of the
rats. There were some pathological fractures in animals after they had developed
bone tumours. Most of the skin tumours described below developed in ulcers.
These late ulcerations of the irradiated areas arose de novo and rapidly took the
form oftypical malignant ulcers. Most ofthese proved on histological examination
to be epidermoid carcinomata, but some were sarcomata arising in soft tissues.
The injections of growth hormone were tolerated without ill effects. Animals
injected with thyroxine were distinctly ill and their fur was ruffled, and although
they did not lose weight the dose of thyroxine was not raised any further for fear
of losing animals.
The mean survival times of the irradiated rats were as follows: Group A
(growth hormone) 513 days; Group B (thyroxine) 504 days; Group C (growth
hormone and thyroxine) 461 days; and Group D (saline) 494 days.
2. The effect ofgrowth hormone on the weight of the rats
The mean weight of the rats at the time of irradiation was 118-120 g. At the
commencement of the injection treatment 80 days later it had increased to 200-
205 g. and the weight curves were beginning to plateau. In the 10 weeks of the
course of injections the 33 irradiated rats injected with saline (Group D) showed
a mean increase of weight of 19-78 ± 1.7 g. per rat. The 30 rats irradiated and
treated with growth hormone (Group A) increased by 26.7 ± 1.77 g. The growth
hormone had caused a small but significant increase in weight (Student's t -2.79,
n 61, p < 0.01). Group C were also treated with growth hormone for 10 weeks
and gained a mean of 25 ± 1.65 g. per rat (t - 2.15, n 59, p < 0.05). The 18
non-irradiated rats of Group H (injected with saline) increased by 22.05 ± 1.88 g.
per rat over the same period, while the non-irradiated rats injected with growth
hormone, Groups E and G, increased by 32.2 ± 3.4; significantly more than the
controls, (t = 2.13, n - 26, p < 0.05). Thus the growth hormone injection
caused a small but significant increase of body weight compared with the rats
receiving saline injections in both the irradiated and non-irradiated rats. Group
B (irradiated rats injected with Na 1 thyroxine) increased by 23.1 ± 19 g. per
rat; this was not significantly different from the saline injected rats.
3. Radiological changes in the bones occurring in thefield of irradiation
The X-ray pictures which were made 185 days after irradiation always showed
some rarefaction of bone with thinning of the cortex. There was retardation of
bone growth and the irradiated bones were always considerably shorter than the
non-irradiated controls. The epiphyseal plates were widened in some animals,
and occasionally detachment or complete destruction of an epiphysis occurred. At
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280 days these changes were usually more pronounced. In 18 ofthe 116 irradiated
survivors one or more transverse bony bars could be seen in the femoral shafts.
Fusion of some epiphyses had occurred. At 386 days there was evidence of repair
of these lesions and of recalcification of the bones in some animals. Twelve rats
had already developed osteosarcomata by this time. Details of the X-ray and
histological changes found in the irradiated bones will be the subject of another
communication.
4. The incidence and induction time of tumours
The overall incidence of malignant tumours in all experimental animals and
in the controls and the induction time of each are given in Fig. 3. It should be
understood that the present classification of mesenchymal tumours into two
groups, osteosarcomata and fibrosarcomata, is purely descriptive. A better
classification may have been obtained by dividing all mesenchymal tumours
according to their site of origin, i.e. bone, periosteum soft tissues. Unfortunately,
the large extension of most of the tumours and their rapid growth, made such
classification impossible or, at best, arbitrary. Under the circumstances, it was
decided to adhere to a descriptive classification, without prejudice to the true site
or origin of each tumour. However, it can be stated, with a reasonable degree of
certainty, that all osteosarcomata originated in bone, and that all fibrosarcomata,
with the notable exceptions mentioned below originated outside the bone, either
from the periosteum or the soft tissues.
Osteosarcomata.-A total of 38 separate osteosarcomata were found in 34 rats
out of a total of 116 irradiated animals. The incidence was higher in the animals
treated with growth hormone, namely 12 out of 30, as compared with 7 out of 31
in the saline-injected animals. The incidence was four times higher in the femur
than in the tibia. The shortest latent period was 251 days (Group B) and 252 days
(Group A, see Fig. 3). In 12 rats osteosarcomata were already present before 386
days (3rd diagnostic X-ray). Fig. 4 shows the diagnostic X-ray at 386 days of an
early osteosarcoma, and Fig. 5 shows the same tumour at post-mortem. The data
on the incidence and mean induction period ofosteosarcomata and fibrosarcomata
are summarized in Table I. Note that the mean induction period ofosteosarcomata
in Group B (thyroxine-treated) is significantly shorter than in the other groups.
(" d" test of Sukhatme (1938) significant at the 5 per cent level.) The mean
induction period offibrosarcomata is the same in all groups which adds significance
TABLE I.-Incidence ofosteosarcomata andfibrosarcomata after irradiation
and hormone treatment
Osteosarcoma Fibrosarcoma
~~~~~~~~~~~~r '^-'-,
Induction Induction
Treatment Incidence % period Incidence % period
Group A, yrays + growth 12/30 40 520+49 . 12/30 40 465±36
hormone
Group B, y rays + thy- 8/29 27-5 388±29 . 9/29 31 468±33
roxine
Group C, y rays + growth 7/26 27 512±35 12/26 46 445±50
hormone and thyroxine
GroupD,yrays +saline. 7/31 22-5 521±46 . 17/31 54.7 441±25
Totals. 34/116 29-3 488±44 50/116 43 453 ±36
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to the finding of a shortened latent period for osteosarcomata in Group B. No
osteosarcomata or fibrosarcomata were found in the unirradiated controls.
The chance of a rat developing a bone sarcoma following irradiation increases
steadily the longer the rat survives. Of the rats which survived more than 200
days after irradiation many died or had to be killed because of sarcomata of soft
tissues or carcinomata of skin or mammary gland. Five rats in Group A and 6
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FIG. 3.-The incidence and induction time of malignant tumours of all types induced by
irradiation and hormone treatment. Each square represents one rat, the number in the
square is the time from irradiation to the detection of the tumour (in days). Note some
rats had more than one type of tumour.
rats in each of Groups B, C, and D had no malignant tumours at death. Of these
23 rats, 9 had pneumonia or pasturella infection, 5 were killed because of very
large fibro-adenomata, 2 had urinary infection, 2 pyometria, 3 pathological
fractures, 1 intestinal obstruction and in 1 no obvious cause of death was found.
The times of these non-specific deaths can be seen in Fig. 3. A life table analysis
was therefore applied to the 4 groups of rats to compare
(1) The chances of developing a bone sarcoma;
(2) The chances of developing a bone sarcoma or a sarcoma of soft tissue;
(3) The chances ofdeveloping any malignant tumour at the site ofirradiation.TUMOURS INDUCED BY GAMMA IRRADIATION OF BONES
A rat was at risk until it developed a tumour of the kind being studied or until it
died from some other cause. Fig. 6 shows the percentage ofrats at risk developing
bone sarcomas. Note that 25 per cent of the rats at risk in Groups A, B and C
have developed an osteosarcoma when 10 per cent of the rats at risk in Group D
PERCENTAGE OF RATS AT RISK WHICH
DEVELOP BONE SARCOMATA/TIME
irowth hormone CA)
rowth hormone (C)
nd thyroxine
;aline CD)
Thyroxine (B)
DAYS
FIG. 6.-Percentage of "rats at risk" which develop bone sarcomata/time. The lower part
of the graph indicates that the growth hormone and thyroxine treated rats develop bone
sarcomata more quickly, the upper part of the graph is based on very few animals and is
therefore of less significance.
have done so. The upper part ofthe graphs are based on very few animals and are
less reliable. More details ofthese life-analysis data are given in Tables II and III.
Description of osteosarcomata.-The osteosarcomata ranged in size from micro-
scopic tumours to large masses up to 40 mm. in maximum dimension. The 13
osteosarcomata found on microscopic examination were all limited to the bone,
but they passed freely through the epiphyseal cartilages from the shaft to the
TABLE II
Percentage of rats at risk which developed
(i) Bone sarcomata in 550 days
(ii) Sarcomata of the bone or soft tissue in 400 days.
(iii) Malignant tumours after 400 days
Treatment
A - --%
A B C D
33.4 30.5 38.1 19-4
32-0 24.7 28-6 29-0
35*6 31-8 41.1 35.5
u.J
z
(.)
ac
a.
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TABLE III
Treatment
Time taken in days for A B C D
(i) 30 per cent of rats at risk to develop bone sarcoma . 548 525 536 654
(ii) 50 per cent of rats at risk to develop sarcomata of bone or 512 517 531 467
soft tissue
(iii) 50 per cent of rats at risk to develop malignant tumours . 467 494 451 488
epiphysis or vice versa. They were all of the so-called "sclerosing type ", with
disorderly arranged, irregular trabeculae, surrounded by a highly cellular tissue
with atypical cells. In all the other instances the tumours spread beyond the
bone, but only 6 of them were typical sclerosing osteosarcomata (Fig. 7 and 8),
while 6 were very cellular tumours that could be recognized as osteosarcomata
only because of the occasional presence of small spicules of bone. The other 14
tumours had a consistent pattern; the central portion showed obvious bone
formation but the peripheral portion consisted of a richly cellular tumour tissue
that could easily be mistaken for a sarcoma arising in soft tissue. There was often
a sharp boundary when one pattern passed into the other (Fig. 9).
Metastases were found in the aortic lymph nodes and lungs of 5 animals:
2 in Group A, and one in each ofthe other groups. Fig. 10 shows a typical example
of a metastasis in lung. In two cases, the metastases were more differentiated than
the primary tumours.
Fibrosarcomata.-The term Fibrosarcoma, as mentioned above, embraces all
the sarcomata that did not produce bone. Most of them were fairly well differen-
tiated fibrosarcomata (Fig. 11) although 7 were anaplastic, undifferentiated and
markedly pleomorphic (Fig. 12). In these instances, it was impossible to deter-
mine with certainty the site oforigin ofthese tumours, but since they did not pro-
duce bone, they were arbitrarily classified as fibrosarcomata.
The 60 fibrosarcomata which were found in 50 animals ranged in size from a
microscopic tumour (arising in or near the periosteum of a rat of Group C killed
at 706 days) to large masses, up to 55 mm. in maximum dimension. In 9 instances,
the tumours were in the subcutaneous tissue, in all other cases the tumours had
invaded the muscles and tissues adjacent to the bones. The femur was replaced
by tumour in 7 cases, the tibia in one, and in other instances there was invasion
of the articular cartilage or replacement of the patella.
Other neoplastic conditions.-An interesting feature was the occurrence of 9
epidermoid carcinomata with a mean induction time of 469 + 29 days and one
basal cell carcinoma arising from irradiated skin. There were 12 glandular carci-
nomata with a mean induction time of 400 + 48 days, probably arising from
irradiated mammary tissue, which in rats extends down to the knees. 23 fibro-
adenomata with a mean induction time of 483 i 35 days were found in the
irradiated rats, but not all of these were in the irradiated areas. Three fibro-
adenomata were found in the 30 control animals. Besides the epidermoid and
glandular carcinomata there were two instances of leukaemia, both in irradiated
rats treated with growth hormone. These rats had greatly enlarged livers and
spleens, myeloid cells were present in the peripheral circulation, and leukaemic
deposits were found in the ovary, adrenal glands, orbit and salivary glands.
Another irradiated rat treated with growth hormone had a carcinoma of the
222TUMOURS INDUCED BY GAMMA IRRADIATION OF BONES
lung. A lymphosarcoma was present in the thymus of two rats, and in another
rat a greatly enlarged hyperplastic thymus was found.
A small adenoma ofthe pituitary was found in 4 rats. In Group A, one ofthese
adenomata showed numerous mitoses.
Small adenocarcinomata of the thyroid were found in 4 rats. Two of these
tumours were present in non-irradiated controls, which were over two years old.
DISCUSSION
A. The dosage of radiation which will induce bone sarcomata
The dosage of radiation which will induce bone sarcomata resolves into two
quite different problems. First, the dosage required in the bone in terms of rad.
This problem we have attempted to solve by the use of gamma radiations from a
192-Iridium source. It has been shown that 3000 r applied to both knee joints of
the rat (equivalent to 4 major epiphyses and 4 cm. of bone shaft) have produced
osteosarcomata in 34 of 116 rats (29.3 per cent), with a mean induction period of
488 ± 44 days.
The second problem concerns the applied dosage of 220 or 250 KVp. X-rays
which would have a similar effect. On the basis of a differential absorption rate
of bone for 220 KVp. X-rays of about 3 times the applied dose, it would be ex-
pected that 1000 r would be equally effective. In 123 irradiated rats at risk,
Koletsky and Gustafson (1955) produced 5 osteogenic sarcomata by using 660 r
of whole-body irradiation. This incidence is not strictly comparable to the inci-
dence of osteosarcomata obtained in our experiments, because of the differences
in the biological effects of whole-body and local irradiation. In the 39 cases of
post-radiation bone sarcomata in man, collectedby Cahan et al., in 1948, the lowest
dose was 1500 r. However, in discussing these cases, Vaughan (1956) noted that,
except for one case following irradiation for fibrous dysplasia and a case ofchondro-
sarcoma following irradiation for a bone cyst, the lowest dose used was 3000 r.
Similarly, of the 13 cases reported by Sabanas et al. (1956) that had received only
external radiation, the total dose was not known in two, it was 10,000 r in a case
of preventive radiation for carcinoma of the breast, and in all the other cases the
radiation treatment was preceded by either a bone cyst or a giant cell tumour,
and the eventual bone sarcomata allarose atthesitesofthepreviouslesions. There-
fore if cases with an antecedent history of bone cyst, fibrous dysplasia or giant
cell tumour are excluded, the lowest dose on record capable of inducing bone
sarcomata in a previously normal bone is 3000 r X-rays. The induction period in
Sabanas' group of cases varied between 32 months and 30 years (average more
than 10 years), while in Cahan's group, it varied between 3 and 32 years, witha
mean of 8.6 years.
The comparative dose in rads of bone-seeking radio-isotopes is difficult to
calculate, but an estimate of the mean radiation dose received by the skeleton
over a given period of time can be made, ifthe energy ofthe radiation emitted by
the isotope, the fraction of the injected activity going to the skeleton and the
effective half-life in the skeleton are known (Lamerton, 1958). By observing the
tables prepared in this way by Lamerton, it appears that with 45-Calcium, 89
and 90-Strontium and 226-Radium, from 2000 to 3000 rads in one year are re-
quired to obtain an incidence of osteo-sarcomata comparable to the one obtained
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in our results. The only exception appears to be 234-Plutonium, for which a dose
of about 500 rads is required.
B. The effect of stimulation of the bone by hormone treatment upon the incidence of
tumours.
The experiment was planned to show whether the stimulation of bone growth
or the rate of bone turnover by hormone treatment would increase the incidence
or shorten the induction period of radiation-induced bone tumours. The incidence
of osteo-sarcomata in children, adolescents and in old people in association with
Paget's disease would indicate that growth changes in the bone are an important
factor in human bone sarcomata. Evans et al. (1948) demonstrated in their classic
experiments the effects of growth hormone on bones, which result in stimulation
of cartilage growth and in periosteal osteogenesis (Becks et al., 1949). The tibias
were longer and the epiphyseal cartilages were wider than in the controls, and all
bones examined histologically showed lines of accretion under the periosteum.
Thcse authors, however, used large doses for periods of time up to 14 months.
On the other hand, thyroxine has been shown to produce maturation ofbone,
(Ray, Asling, Simpson and Evans, 1950; Simpson, Asling and Evans, 1950);
this was revealed by the full development of the ossification centres, atrophy of
the epiphyseal cartilage and closure on the epiphyseal side, while the calcium and
nitrogen contents were decreased (Baisset, Doust-Blazy, Montastruc and Planel
1954). In man, Follis (1953) has shown that hyperthyroidism produces osteitis
fibrosa, osteomalacia and osteoporosis, and Wilkins (1955) observed delayed
maturation of bone in hyperthyroidism.
With regard to growth hormone our experiments have not given a statistically
valid answer, though the data do suggest a trend toward an increased incidence
of osteosarcomata in the growth hormone treated group. However, treatment
with thyroxine shortened the induction period of osteosarcoma and this finding
is statistically significant. Though our doses of growth hormone were much
smaller than those used by Evans et al. (1948) they were sufficient to induce a
small but significant increase of growth. However, in the rat, even in the female,
growth never really ceases, as the proximalepiphyses oftibia, humerus andfibula,
and the distal epiphyses of radius and ulna close normally at an average age of
EXPLANATION OF PLATES
FIG. 4.-Diagnostic X-ray showing an early osteosarcoma of left tibia 386 days after irradia-
tion (thyroxine-treated rat).
FIG. 5.-X-ray of the same rat at post-mortem (436 days after irradiation).
FIa. 7.-X-ray at post-mortem 720 days after irradiation showing osteosarcomata of both
femora (rat had been treated with growth hormone and then thyroxine). The tumour
on the left side had been present for 51 days, the one on the right side for 9 days. The large,
round shadow on the right side is due to a fibro-adenoma.
FIG. 8.-Photomicrograph of the osteosarcoma of the left femur illustrated in Fig. 7. X 2.
FIG. 9.-Photomicrograph illustrating the sharp boundary between the bone-forming (below)
and the fleshy portions (above) of an osteosarcoma. (Irradiated rat treated with thryoxine,
283 days after irradiation, x 100).
FIG. 10.-Sclerosing osteosarcoma, metastasis in lung 489 days after irradiation (saline injected
group D). x 100.
FIG. 11.-Fibrosarcoma invading muscle (irradiated rat treated with growth hormone; 452
days after irradiation). x 275. Note the striated muscle fibre.
FIG. 12.-Anaplastic sarcoma (irradiated rat treated with saline; 294 days after irradiation).
x 275.
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1135 days (Dawson, 1925), and it is possible that an extensive and prolonged
alteration of the growth of bones must be induced before a striking effect can be
demonstrated on the incidence of bone sarcomata. The rats were only 60 days
old at the time of irradiation, therefore a marked proliferation of cells could be
expected after the irradiation due to the natural growth ofthe bones. The growth
of the irradiated bone was retarded compared with the unirradiated control, but
some growth did take place and this might account for the considerable incidence
of bone sarcomata in the irradiated group which was not treated with growth
hormone.
Still, the incidence ofosteosarcomata in growth hormone treated rats was some-
what higher than in controls, and the induction period in the thyroxine group was
shorter, and in evaluating these results, one should not forget that these hormones
did not have any appreciable effect on the incidence or induction period ofthe soft
tissue sarcomata.
C. The incidence of other neoplastic conditions
In our experiments, 3000 r of gamma radiation induced 60 fibrosarcomata in
50 out of 116 rats. Though it is generally thought that post-irradiation sarcomata
ofthe soft tissues are a rarity, experimental and clinical evidence support the view
that this is not an infrequent complication of radiation. Warren (1943) has men-
tioned such a possibility, and Jones (1953) has reviewed the literature to which
he added a case of his own, of soft tissue post-radiation sarcomata occurring in
man. With 660 r of whole-body irradiation with X-rays, Koletsky and Gustafson
(1955) produced 14 fibrosarcomata out of 123 irradiated rats at risk; this inci-
dence can be compared with 50 fibrosarcomata produced by 3000 r ofgamma rays
given locally in the present studies. Sarcomata of the soft tissues were also pro-
duced by Binhammer, Finerty, Schneider and Cunningham (1957) in single sub-
lethally irradiated rats, and in parabiotic rats receiving 700 roentgens of X-rays.
The 12 cases of mammary adenocarcinomata produced in our experiments are
not surprising, as radiation is known to increase the incidence of mammary carci-
nomata in rats. Actually, our incidence is low, when compared with the results
obtained by Binhammer et al., (1957) and by Shellabarger, Cronkite, Bond and
Lippincott (1957) with whole-body irradiation, where the majority of the
tumours produced were mammary carcinomata, but in whole-body irradiation
the induced endocrine disturbance may be an important factor. The other
tumours recorded in our experiments are not attributable to radiation, as their
incidence was not significantly above that of non-irradiated rats. This applied
also to the thyroid carcinomata, which have been shown (Lindsay, Potter and
Chaikoff, 1957), to occur spontaneously in a high percentage of normal Long-
Evans rats.
SUMMARY
1. A single dose of 3000 roentgen of gamma irradiation from a 192Iridium
teletherapy source applied to both knee joints of growing female rats induced
osteosarcomata in 34 out of 116 rats. 50 rats developed sarcomata of soft tissues,
10 cancer of the skin, and 12 had mammary cancers.
2. 80 days after irradiation, ten-week courses of (A) growth hormone, (B)
thyroxine (C) growth hormone followed by thyroxine and (D) saline were given
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to study the effect ofhormone treatment on the incidence and induction period of
radiation-induced bone sarcomata.
3. 12 out of 30 growth hormone treated rats developed bone sarcomata com-
pared with 7 out of 31 in the saline injected group.
4. Thyroxine treatment significantly reduced the mean latent period of radia-
tion-induced osteosarcomata (521 ± 46 days in control Group D; 388 i 35 days
in Group B).
5. The incidence of other types of malignant tumours was not affected by the
hormone treatments.
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